Clinical Trials Browser

Recurrence × pembrolizumab × CNS × Clear all

NCT01822652 2025-02-24

GRAIN

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

NCT02337491 2020-12-22

Pembrolizumab +/- Bevacizumab for Recurrent GBM

Phase 2 Completed

80 enrolled 13 charts

Glioblastoma, Recurrence